Inhibition of death receptor signals by cellular FLIP

被引:2094
作者
Irmler, M
Thome, M
Hahne, M
Schneider, P
Hofmann, B
Steiner, V
Bodmer, JL
Schroter, M
Burns, K
Mattmann, C
Rimoldi, D
French, LE
Tschopp, J
机构
[1] UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND
[2] UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND
[3] SWISS INST EXPT CANC RES,BIL BIOMED RES CTR,CH-1066 EPALINGES,SWITZERLAND
[4] UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND
关键词
D O I
10.1038/40657
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The widely expressed protein Fas is a member of the tumour necrosis factor receptor family which fan trigger apoptosis(1). However, Fas surface expression does not necessarily render cells susceptible to Fas ligand-induced death signals(1,2), indicating that inhibitors of the apoptosis-signalling pathway must exist. Here we report the characterization of an inhibitor of apoptosis, designated FLIP (for FLICE-inhibitory protein), which is predominantly expressed in muscle and lymphoid tissues. The short form, FLIPS, contains two death effector domains and is structurally related to the viral FLIP inhibitors of apoptosis(3), whereas the long form, FLIPL, contains in addition a caspase-like domain in which the active-centre cysteine residue is substituted by a tyrosine residue. FLIPS and FLIPL interact with the adaptor protein FADD(4,5) and the protease FLICE6,7, and potently inhibit apoptosis induced by all known human death receptors(1). FLIPL is expressed during the early stage of T-cell activation, but disappears when T cells become susceptible to Fas ligand-mediated apoptosis. High levels of FLIPL protein are also detectable in melanoma cell lines and malignant melanoma tumours. Thus FLIP may be implicated in tissue homeostasis as an important regulator of apoptosis.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 30 条
  • [1] Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis
    Bertin, J
    Armstrong, RC
    Ottilie, S
    Martin, DA
    Wang, Y
    Banks, S
    Wang, GH
    Senkevich, TG
    Alnemri, ES
    Moss, B
    Lenardo, MJ
    Tomaselli, KJ
    Cohen, JI
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) : 1172 - 1176
  • [2] BODNER JL, 1997, IMMUNITY, V6, P79
  • [3] A NOVEL PROTEIN THAT INTERACTS WITH THE DEATH DOMAIN OF FAS/APO1 CONTAINS A SEQUENCE MOTIF RELATED TO THE DEATH DOMAIN
    BOLDIN, MP
    VARFOLOMEEV, EE
    PANCER, Z
    METT, IL
    CAMONIS, JH
    WALLACH, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (14) : 7795 - 7798
  • [4] Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
    Boldin, MP
    Goncharov, TM
    Goltsev, YV
    Wallach, D
    [J]. CELL, 1996, 85 (06) : 803 - 815
  • [5] A flexible motif search technique based on generalized profiles
    Bucher, P
    Karplus, K
    Moeri, N
    Hofmann, K
    [J]. COMPUTERS & CHEMISTRY, 1996, 20 (01): : 3 - 23
  • [6] INHIBITION OF ICE FAMILY PROTEASES BY BACULOVIRUS ANTIAPOPTOTIC PROTEIN P35
    BUMP, NJ
    HACKETT, M
    HUGUNIN, M
    SESHAGIRI, S
    BRADY, K
    CHEN, P
    FERENZ, C
    FRANKLIN, S
    GHAYUR, T
    LI, P
    LICARI, P
    MANKOVICH, J
    SHI, LF
    GREENBERG, AH
    MILLER, LK
    WONG, WW
    [J]. SCIENCE, 1995, 269 (5232) : 1885 - 1888
  • [7] FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS
    CHINNAIYAN, AM
    OROURKE, K
    TEWARI, M
    DIXIT, VM
    [J]. CELL, 1995, 81 (04) : 505 - 512
  • [8] In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains
    FernandesAlnemri, T
    Armstrong, RC
    Krebs, J
    Srinivasula, SM
    Wang, L
    Bullrich, F
    Fritz, LC
    Trapani, JA
    Tomaselli, KJ
    Litwack, G
    Alnemri, ES
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7464 - 7469
  • [9] FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249
  • [10] INTERLEUKIN-1-BETA CONVERTING-ENZYME REQUIRES OLIGOMERIZATION FOR ACTIVITY OF PROCESSED FORMS IN-VIVO
    GU, Y
    WU, JW
    FAUCHEU, C
    LALANNE, JL
    DIU, A
    LIVINGSTON, DJ
    SU, MSS
    [J]. EMBO JOURNAL, 1995, 14 (09) : 1923 - 1931